ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Significant Decline in Short Interest

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 309,400 shares, a decrease of 20.7% from the July 15th total of 390,000 shares. Based on an average daily trading volume, of 232,500 shares, the days-to-cover ratio is currently 1.3 days.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ANIP. Truist Financial lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Wednesday, August 7th. Finally, Guggenheim reiterated a “buy” rating and set a $77.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $82.75.

Insiders Place Their Bets

In other news, SVP Ori Gutwerg sold 2,985 shares of the stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $67.00, for a total transaction of $199,995.00. Following the transaction, the senior vice president now owns 77,227 shares of the company’s stock, valued at approximately $5,174,209. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, SVP Ori Gutwerg sold 2,985 shares of the business’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $67.00, for a total value of $199,995.00. Following the completion of the sale, the senior vice president now directly owns 77,227 shares in the company, valued at $5,174,209. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Muthusamy Shanmugam sold 20,000 shares of the firm’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $58.90, for a total transaction of $1,178,000.00. Following the completion of the transaction, the chief operating officer now owns 682,620 shares in the company, valued at $40,206,318. The disclosure for this sale can be found here. Insiders have sold 108,847 shares of company stock valued at $6,815,417 over the last three months. 12.70% of the stock is currently owned by insiders.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Texas Permanent School Fund Corp boosted its stake in ANI Pharmaceuticals by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock worth $912,000 after purchasing an additional 172 shares in the last quarter. New York State Teachers Retirement System grew its holdings in ANI Pharmaceuticals by 0.9% during the 4th quarter. New York State Teachers Retirement System now owns 22,380 shares of the specialty pharmaceutical company’s stock worth $1,234,000 after acquiring an additional 200 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in ANI Pharmaceuticals by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after acquiring an additional 200 shares during the last quarter. Arizona State Retirement System increased its position in ANI Pharmaceuticals by 4.7% in the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after acquiring an additional 211 shares in the last quarter. Finally, Simplicity Wealth LLC raised its stake in shares of ANI Pharmaceuticals by 3.5% in the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after acquiring an additional 227 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded down $1.08 during trading on Friday, hitting $60.02. 175,898 shares of the stock were exchanged, compared to its average volume of 179,235. ANI Pharmaceuticals has a 1-year low of $48.20 and a 1-year high of $70.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.12 and a current ratio of 3.95. The company’s fifty day simple moving average is $62.21 and its 200-day simple moving average is $63.33. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of 37.51 and a beta of 0.75.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. The company had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. During the same period in the prior year, the company posted $1.06 EPS. The company’s revenue was up 18.5% compared to the same quarter last year. Sell-side analysts expect that ANI Pharmaceuticals will post 3.3 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.